Loading...
Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program
BACKGROUND: Belimumab is a recombinant, human, IgG1λ monoclonal antibody that targets B-lymphocyte stimulator. The intravenous formulation is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE). Belimumab has been formulated for subcutaneous (SC) administr...
Na minha lista:
| Udgivet i: | Lupus |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5054300/ https://ncbi.nlm.nih.gov/pubmed/27072354 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203316642309 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|